{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:09:10Z","timestamp":1789002550896,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic graft-versus-host disease (cGvHD) is a common complication that can occur following hematopoietic stem cell transplantation. This complex, multisystemic condition often requires multiple lines of therapy to treat both the symptoms of cGvHD and the side effects associated with these treatments. Comprehensive data on the impact of cGvHD on health-related quality of life (HRQoL) of patients who have undergone multiple lines of therapy, remain limited. Greater awareness of these challenges could lead to more personalized treatment plans and inform future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a two-part study to gather qualitative and quantitative data on the experiences and HRQoL of adult patients with cGvHD who had received more than two lines of therapy. Participants took part in a virtual, in-depth interview moderated by a facilitator (qualitative interviews) and\/or an online survey (quantitative survey). The qualitative interviews were conducted using a discussion guide, while the quantitative survey designed based on the responses to the qualitative interview also included the European Quality of Life 5 Dimensions 5 Level Version questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The qualitative interview included 10 participants, while the quantitative survey enrolled 27. patients reported that cGvHD has a profound impact on numerous aspects of HRQoL. Treatment side effects, treatment burden, frequency of medical appointments, and the impact on daily life, finances, education, and mental health were all contributors to diminished HRQoL. Patients reported feeling unprepared for the severity and longevity of cGvHD symptoms and highlighted the need for improved communication between healthcare professionals (HCPs) treating the same patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>cGvHD significantly impacts the HRQoL of patients, with physical, emotional, and financial burdens. Improved education and disease awareness, personalized treatment plans, and better communication between HCPs treating the same patient are crucial to address these challenges in current care practices. Enhanced support services could alleviate the emotional and financial impact on patients, ultimately improving their overall quality of life (QoL).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12955-026-02571-3","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:34:08Z","timestamp":1782405248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating the impact of chronic graft\u2011versus\u2011host disease on patient health\u2011related quality of life: perspectives from patients and carers"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9376-5451","authenticated-orcid":false,"given":"Katharina","family":"Ecsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Furze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Sugden","family":"Heron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adlene","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunesh","family":"Sil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D. A.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bradberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"7","key":"2571_CR1","first-page":"545","volume":"27","author":"CL Kitko","year":"2021","unstructured":"Kitko CL, Pidala J, Schoemans HM, Lawitschka A, Flowers ME, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transpl Cell Ther. 2021;27(7):545\u201357.","journal-title":"Transpl Cell Ther"},{"issue":"12\u2013b Suppl","key":"2571_CR2","first-page":"S2","volume":"28","author":"B Flavin","year":"2022","unstructured":"Flavin B. Chronic graft-vs-host disease: Current understanding of disease and treatment landscape. J Manag Care Spec Pharm. 2022;28(12\u2013b Suppl):S2\u201312.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"2571_CR3","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","volume":"56","author":"D Wolff","year":"2021","unstructured":"Wolff D, Fatobene G, Rocha V, Kr\u00f6ger N, Flowers ME. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transpl. 2021;56(9):2079\u201387.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"2571_CR4","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157\u201367.","journal-title":"Lancet Haematol"},{"issue":"6","key":"2571_CR5","first-page":"e5041","volume":"27","author":"CR Bachier","year":"2021","unstructured":"Bachier CR, Aggarwal SK, Hennegan K, Milgroom A, Francis K, Dehipawala S, et al. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis. Transpl Cell Ther. 2021;27(6):e5041\u20136.","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2571_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.18053\/jctres.09.202302.006","volume":"9","author":"JI Nolazco","year":"2023","unstructured":"Nolazco JI, Chang SL. The role of health-related quality of life in improving cancer outcomes. J Clin Transl Res. 2023;9(2):110\u201314.","journal-title":"J Clin Transl Res"},{"key":"2571_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3899\/jrheum.110906","volume":"88","author":"GA Wells","year":"2011","unstructured":"Wells GA, Russell AS, Haraoui B, Bissonnette R, Ware CF. Validity of quality of life measurement tools-from generic to disease-specific. J Rheumatol Suppl. 2011;88:2\u20136.","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"2571_CR8","first-page":"3","volume":"58","author":"SMS Lavi\u00f1a","year":"2024","unstructured":"Lavi\u00f1a SMS. Measuring Quality of Life through Validated Tools. Acta Med Philipp. 2024;58(10):3\u20134.","journal-title":"Acta Med Philipp"},{"issue":"4","key":"2571_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","volume":"19","author":"RP McQuellon","year":"1997","unstructured":"McQuellon RP, Russell GB, Cella DF, Craven BL, Brady M, Bonomi A, et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transpl. 1997;19(4):357\u201368.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2571_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","volume":"26","author":"C Teh","year":"2020","unstructured":"Teh C, Onstad L, Lee SJ. Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale. Biol Blood Marrow Transpl. 2020;26(3):562\u201367.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2571_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","volume":"30","author":"YS Feng","year":"2021","unstructured":"Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the Eq.\u00a05D-5L: a systematic review of the literature. Qual Life Res. 2021;30(3):647\u201373.","journal-title":"Qual Life Res"},{"issue":"10","key":"2571_CR12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41409-024-02370-8","volume":"59","author":"G Vadakkel","year":"2024","unstructured":"Vadakkel G, Eng S, Proli A, Ponce DM. Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era. Bone Marrow Transpl. 2024;59(10):1360\u201368.","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2571_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46989\/001c.124926","volume":"6","author":"R Shah","year":"2024","unstructured":"Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al. Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. Clin Hematol Int. 2024;6(4):74\u201388.","journal-title":"Clin Hematol Int"},{"issue":"6","key":"2571_CR14","doi-asserted-by":"publisher","first-page":"e730","DOI":"10.1097\/HS9.0000000000000730","volume":"6","author":"A Zelic Kerep","year":"2022","unstructured":"Zelic Kerep A, Pirsl F, Steinberg S, Mitchell S, Curtis L, Holtzman N, et al. Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. Hemasphere. 2022;6(6):e730.","journal-title":"Hemasphere"},{"issue":"3","key":"2571_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21(3):389\u2013e4011.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"17","key":"2571_CR16","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","volume":"117","author":"J Pidala","year":"2011","unstructured":"Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651\u20137.","journal-title":"Blood"},{"issue":"8","key":"2571_CR17","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","volume":"108","author":"CJ Fraser","year":"2006","unstructured":"Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108(8):2867\u201373.","journal-title":"Blood"},{"issue":"1","key":"2571_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","volume":"158","author":"FL Dignan","year":"2012","unstructured":"Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol. 2012;158(1):46\u201361.","journal-title":"Br J Haematol"},{"issue":"4","key":"2571_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"ME Flowers","year":"2015","unstructured":"Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606\u201315.","journal-title":"Blood"},{"issue":"17","key":"2571_CR20","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1182\/bloodadvances.2022007611","volume":"7","author":"NP Buxbaum","year":"2023","unstructured":"Buxbaum NP, Soci\u00e9 G, Hill GR, MacDonald KPA, Tkachev V, Teshima T, et al. Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD. Blood Adv. 2023;7(17):4886\u2013902.","journal-title":"Blood Adv"},{"issue":"9S","key":"2571_CR21","first-page":"S559","volume":"30","author":"A Barata","year":"2024","unstructured":"Barata A, Tavori G, Wolff D, Herrmann A. Patient and Physician Communication in the Allogeneic Transplantation Setting: Challenges and Potential Solutions. Transpl Cell Ther. 2024;30(9S):S559\u201369.","journal-title":"Transpl Cell Ther"},{"key":"2571_CR22","doi-asserted-by":"publisher","first-page":"103993","DOI":"10.1016\/j.critrevonc.2023.103993","volume":"186","author":"R Ji","year":"2023","unstructured":"Ji R, Li Y, Huang R, Xiong J, Wang X, Zhang X. Recent advances and research progress in biomarkers for chronic graft versus host disease. Crit Rev Oncol Hematol. 2023;186:103993.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"2571_CR23","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.bbmt.2019.06.024","volume":"25","author":"JM Jacobs","year":"2019","unstructured":"Jacobs JM, Fishman S, Sommer R, Sereno I, Fenech A, Jankowski AL, et al. Coping and modifiable psychosocial factors are associated with mood and quality of life in patients with chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2019;25(11):2234\u201342.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2571_CR24","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41409-020-0782-z","volume":"55","author":"G Di Giuseppe","year":"2020","unstructured":"Di Giuseppe G, Thacker N, Schechter T, Pole JD. Anxiety, depression, and mental health-related quality of life in survivors of pediatric allogeneic hematopoietic stem cell transplantation: a systematic review. Bone Marrow Transpl. 2020;55(7):1240\u201354.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2571_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/hematology.2021000302","volume":"2021","author":"A El-Jawahri","year":"2021","unstructured":"El-Jawahri A. What else do I need to worry about when treating graft-versus-host disease? Hematol Am Soc Hematol Educ Program. 2021;2021(1):655\u201361.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"2571_CR26","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.bbmt.2018.07.020","volume":"24","author":"A El-Jawahri","year":"2018","unstructured":"El-Jawahri A, Pidala J, Khera N, Wood WA, Arora M, Carpenter PA, et al. Impact of psychological distress on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2018;24(11):2285\u201392.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2571_CR27","first-page":"e4701","volume":"29","author":"J Yu","year":"2023","unstructured":"Yu J, Khera N, Turnbull J, Stewart SK, Williams P, Bhatt V, et al. Impact of chronic graft-versus-host disease on patient employment, income, and informal caregiver burden: findings from the Living With Chronic GVHD Patient Survey. Transpl Cell Ther. 2023;29(7):e4701\u20139.","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2571_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.bbmt.2018.09.040","volume":"25","author":"N Khera","year":"2019","unstructured":"Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, et al. Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biol Blood Marrow Transpl. 2019;25(3):599\u2013605.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2571_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40487-024-00288-1","volume":"12","author":"BK Hamilton","year":"2024","unstructured":"Hamilton BK, Williams P, Galvin J, Turnbull J, Yu J. Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey. Oncol Ther. 2024;12(3):451\u201364.","journal-title":"Oncol Ther"},{"issue":"8","key":"2571_CR30","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.bbmt.2016.05.008","volume":"22","author":"GA Abel","year":"2016","unstructured":"Abel GA, Albelda R, Khera N, Hahn T, Salas Coronado DY, Odejide OO, et al. Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2016;22(8):1504\u201310.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-026-02571-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-026-02571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-026-02571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:05:34Z","timestamp":1789002334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12955-026-02571-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1186\/s12955-026-02571-3","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KE, AA, AS, and RH are employees of Sanofi. KE, AS, RH, and MB are stockholders of Sanofi. LS, MB and MF were employees of Sanofi at the time of the study. CSH and AP are employees of Synergy Healthcare Research, which received funding from Sanofi to undertake the market research element of the current study, and other, unrelated studies. LD was an employee of Synergy Healthcare Research at the time of the study. DH declares no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}